



10th Anniversary Instituto Roche Forum on Personalized Medicine: Challenges for the Next Decade

BIOSPAIN 2014,
Santiago de Compostela (Spain)
Palacio de Congresos e Exposiciones

September 25th 2014

 #PersMedForum



biospain
2014

Instituto Roche Forum on Personalized Medicine: Challenges for the next decade

Since its foundation in 2004, Instituto Roche has worked to disseminate the concept of Personalized Healthcare, by fostering education, debate and consensus among all stakeholders in the healthcare system: academia, clinicians, pharmacists, healthcare managers and policy makers, patients and the media.

On the occasion of its 10th Anniversary Instituto Roche organizes an international Forum on Personalized Medicine, where the concept will be approached from a multidisciplinary perspective. The Forum will be a part of BIOSPAIN 2014, the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world.

The symposium will present advances in the field of Personalized Medicine in biomedical research, diagnosis and public health policies.

Agenda

09:00 – 09:30
Opening

09:30 – 10:30
**Keynote Speech: Moving
Genomics to the Clinic:
Opportunities and Challenges**

Gerardo Jiménez-Sánchez

*Harvard School of Public Health, USA
and Global Biotech Consulting Group,
México.*

10:30 – 11:30

**Session 1:
Scientific and Technologic
Advances in Biomedicine**

Chairman: Ángel Carracedo

*Director, Galician Public Foundation for
Genomic Medicine. Spain.*

**Genomes, epigenomes and
future perspectives in
Personalized Medicine**

Manel Esteller

*Director and Group Leader, Cancer
Epigenetics and Biology Program
(PEBC), Bellvitge Biomedical
Research Institute (IDIBELL), Spain.*

**Bioinformatics and Big Data in the
era of Personalized Medicine**

Joaquín Dopazo

*Head of the Computational Genomics
Department, Centro de Investigación
Príncipe Felipe, Spain.*

Discussion

11:30 – 12:00
Coffee Break

12:00 – 14:00

Session 2:

Innovation, research and Public Health policies in Personalized Medicine

Chairman: Rafael López

Oncology Director. Complejo Hospitalario Universitario de Santiago. Spain.

European policies in Personalized Medicine

Isabel de la Mata

Principal Advisor with Special Interest in Public Health, DG Health and Consumers, European Commission. Belgium.

Pharma access to external innovation: the example of Roche

María Bobadilla

Senior Director, Extending Innovation Network, Roche Partnering. Switzerland.

Breaking down walls in biomedical research and the challenge of patents in Spain: a success story

Carlos Buesa

Chief Executive Officer. ORYZON. Spain.

Spanish strategy for research on Personalized Medicine: collaborations between academic institutions and the private sector.

Antonio L. Andreu

Director, Instituto de Salud Carlos III. Spain.

Discussion

14:00 – 15:00

Lunch

Biotechnology & human genome sequencing: socio-economic & health impact

The continuously growing use of Next Generation Sequencing (NGS) is profoundly changing the practice of the medicine. Since research on this area has been very successful in the discovery of genes causing mendelian disorders and cancer, NGS is becoming a useful tool for the implementation of personalized medicine. Among other causes, the lowering price of the technology is accounting for its popularity, probably placing some genomic tests at cost levels similar to many non-genetic analytical tests.

However, in spite of the undeniable potential as the milestone of personalized medicine, to fully become of clinical use, NGS faces a number of challenges in terms of technology, validation, data management and ethics that have to be deal with.

The session will focus on the discussion and the identification of some of these problems: economical impact of the implementation of the technology at the National Health Systems, , major technical challenges in data management and security, fitness of the Systems to cope with the advances (professional profiles equality of access to the best possible medicine), future of the predictive medicine based on genomic tests, role of the biotechnology companies as service providers for clinical management.

15:00 – 16:30

**Session 3:
Biotechnology & human genome
sequencing: socio-economic &
health impact.**

Chairman: Javier García Planells

Director Científico de IMEGEN;

*Presidente de la Asociación Española de
Diagnóstico Prenatal. Spain.*

**Genomic medicine: Opportunities
and challenges to the
bioeconomy.**

Gerardo Jiménez-Sánchez

*Harvard School of Public Health, USA
and Global Biotech Consulting Group,
México.*

**Adoption of Next Generation
Sequencing on the National
Health System: impact and
experience of an early adopter.**

Gert Matthijs

*Center for Human Genetic, University
Hospital, Leuven , Belgium.*

**Implementation of genomic
medicine in Spain: lights, shadows
and future**

Juan C. Cigudosa

*Spanish National Cancer Research
Center, Madrid. President, Spanish
Association of Human Genetics. Spain.*

**Spanish Human Proteome Project
of Chromosome 16:**

Rheumatologic Application

Francisco J. Blanco

*Scientific Director INIBIC - Instituto de
Investigación Biomédica da Coruña.
Spain.*

Información e inscripciones en:
www.instituto-roche.es

Síguenos en:



biospain
2014